文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

每日与每周前列腺癌图像引导放射治疗:3期多中心随机试验

Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-07-31

该3期多中心随机试验纳入470例N0局限期前列腺癌患者,随机分为每日与每周图像引导放射治疗(IGRT)两组,比较5年无复发生存及毒性。结果显示两组无复发生存无显著差异,但每日组总生存更差,急性及晚期直肠毒性更低,生化进展无进展间期更优。

要点

  • 每日IGRT组与每周组5年无复发生存无统计学显著差异(HR=0.81,P=.330)。
  • 每日组总生存较每周组差(HR=2.12,95%CI 1.03-4.37,P=.042)。
  • 每日组急性直肠出血(≥1级)6%低于每周组11%(P=.014),晚期直肠毒性也显著更低(HR=0.71,P=.027)。

核心结论

  • 与每周对照相比,前列腺癌每日IGRT显著改善生化进展无进展间期、临床进展无进展间期和直肠毒性。

研究设计与样本

  • 3期多中心随机试验,2007年6月至2012年11月从21个中心招募470例N0局限期前列腺癌患者,1:1随机分入每日IGRT组和每周IGRT组,中位随访4.1年。

主要发现

  • 两组无复发生存无统计学显著差异(HR=0.81,P=.330)。
  • 每日组总生存较每周组差(HR=2.12,95%CI 1.03-4.37,P=.042)。
  • 每日组急性直肠出血(≥1级)6%(n=14)显著低于每周组11%(n=26)(P=.014)。
  • 每日组晚期直肠毒性(≥1级)显著低于每周组(HR=0.71,95%CI 0.53-0.96,P=.027)。
  • 每日组生化进展无进展间期更优(HR=0.45,95%CI 0.25-0.80,P=.007),临床进展无进展间期更优(HR=0.50,95%CI 0.24-1.02,P=.057),其他无癌间期更差(HR=2.21,95%CI 1.10-4.44,P=.026)。

关键数值与推荐

  • 前列腺总IGRT剂量70 Gy至80 Gy,淋巴结豁免照射。
  • 每周IGRT组于第1、2、3天及随后每周进行。
  • 主要终点为5年无复发生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal frequency of prostate cancer image guided radiation therapy (IGRT) has not yet been clearly identified. This study sought to compare the safety and efficacy of daily versus weekly IGRT. MATERIALS AND METHODS: This phase 3 randomized trial recruited patients with N0 localized prostate cancer. The total IGRT doses in the prostate ranged from 70 Gy to 80 Gy, sparing the lymph nodes. Patients were randomly assigned (1:1) to 2 prostate IGRT frequency groups: daily and weekly (ie, on days 1, 2, and 3 and then weekly). The primary outcome was 5-year recurrence-free survival. Secondary outcomes included overall survival and toxicity. Post hoc analyses included biochemical progression-free interval, clinical progression-free interval, and other cancer-free interval. RESULTS: Between June 2007 and November 2012, 470 men from 21 centers were randomized into the 2 groups. Median follow-up was 4.1 years. There was no statistically significant difference in recurrence-free survival between the groups (hazard ratio [HR] = 0.81; P = .330). Overall survival was worse in the daily group than in the weekly group (HR = 2.12 [95% confidence interval (CI), 1.03-4.37]; P = .042). Acute rectal bleeding (grade ≥1) was significantly lower in the daily group (6%) (n = 14) than in the weekly group (11%) (n = 26) (P = .014). Late rectal toxicity (grade ≥1) was significantly lower in the daily group (HR = 0.71 [95% CI, 0.53-0.96]; P = .027). Biochemical progression-free interval (HR = 0.45 [95% CI, 0.25 - 0.80]; P = .007) and clinical progression-free interval (HR = 0.50 [95% CI, 0.24-1.02]; P = .057) were better in the daily group, whereas other cancer-free interval was worse in the daily group (HR = 2.21 [95% CI, 1.10-4.44]; P = .026). CONCLUSIONS: Compared with weekly control, daily IGRT control in prostate cancer significantly improves biochemical progression-free and clinical progression-free interval, and rectal toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. de Crevoisier R, Bayar MA, Pommier P, et al. Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 30071296. doi:10.1016/j.ijrobp.2018.07.2006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。